713-621-4629 al.levi@usisearch.com
Select Page

Send new requirements for the transfer of enterprise equipment (VMA) and other non-monetary agreements (for example. B data usage and collaboration agreements) and show the status of existing requirements. Send new requirements for company-sponsored search and status display. Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on eye diseases, announced today that the company has entered into a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can result in permanent vision loss. Gyroscope has an exclusive IP option related to and resulting research under the agreement. A team of CAROT and Gyroscope researchers will work together to study specific gene therapy targets for glaucoma, optic neuritis and retinitis pigmentosa. The carot team is led by Jean Bennett, M.D., Ph.D., F.M Kirby Professor of Ophthalmology, with Ken Shindler, M.D., Ph.D., an ophthalmology professor, and Ahmara Ross, M.D., Ph.D., an assistant professor of ophthalmology, Perelman School of Medicine. Khurem Farooq, Chief Executive Officer, Gyroscope said: Gyroscope Therapeutics and the University of Pennsylvania give the Philadelphia Research Agreement, May 28, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of T cell therapies for patients with childhood B cell disease.

The agreement expands the scope of research funded by three other B-cell-mediated autoimmune diseases led by Aimee Payne, M.D., Ph.D., Associate Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, Director of the Penn Clinical Autoimmunity Center of Excellence and co-founder of Cabaletta Bio and co-chair of the Scientific Advisory Board. Faculty at the University of Agricultural Sciences are also subject to specific rules because of their preservation of the formula funds of the U.S. Department of Agriculture. Ag`s Faculty of Science should consult with its Grants Contracts Office to determine if you can use the Sponsored Research Agreement – Ag Science Version or any of the other model agreements below. “Over the past two years, our collaboration with Dr. Paynes` laboratory has resulted in two candidates, including our main clinical program at Mucosal pemphigus vulgaris and our leading preclinical program in MuSK myasthenia gravis, which is now embarking on new drug (IND) investigation studies.

Share This